Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 + Pembrolizumab in Melanoma and RCC
NCT03111901Phase 2Withdrawn
- Start
- Oct 2018
- Primary completion
- Oct 2023
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label trial of aldesleukin in melanoma and renal cell carcinoma (RCC) (2 arms). Primary endpoints: Adverse Event Profile, Disease Control Rate (Melanoma) and 1 more. Planned start Oct 2018; status: withdrawn.
02
Drugs
aldesleukin
03
Conditions
melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03111901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03111901.